CDNA vs PBYI: fair value comparison
CareDx, Inc. and Puma Biotechnology, Inc. · Updated 2026-10-19
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, CDNA currently sits closer to the top of our ranking by discount to fair value.
| CDNA | PBYI | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $64.00 | $9.83 |
| 12-month range | $14.28–$69.85 | $4.73–$10.52 |
| Rank by discount to fair value | #94 of 108 Healthcare | #95 of 108 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Uptrend |
| DCF cross-check | — | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: CDNA fair value analysis · PBYI fair value analysis